<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04822532</url>
  </required_header>
  <id_info>
    <org_study_id>BuGenes 01</org_study_id>
    <nct_id>NCT04822532</nct_id>
  </id_info>
  <brief_title>Precision Dosing of Busulfan in Children Undergoing HSCT</brief_title>
  <acronym>BuGenes01</acronym>
  <official_title>Implementing Pharmacogenetics in the Busulfan Dosing Method for Children Undergoing Hematopoietic Stem-cell Transplantation: a Prospective, Multicentric, Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Geneva</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Geneva</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this clinical trial is to evaluate the personalization the conditioning&#xD;
      regimen prior to the hematopoietic stem cell transplant (HSCT) in children and adolescents,&#xD;
      to improve HSCT efficacy while reducing conditioning-related toxicities. Namely, we are going&#xD;
      to compare the accuracy of two methods for determining the first dose of busulfan, one of the&#xD;
      medicines used during the conditioning regimen. First doses will be determined based either&#xD;
      only on anthropometric information such as age and weight or by adding a genetic factor that&#xD;
      influences the individual ability of busulfan metabolization.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will be randomly assigned (1:1 ratio, stratified by conditioning regimen - the&#xD;
      presence of fludarabine) to receive their first dose of busulfan according to:&#xD;
&#xD;
        1. the most performing method based on age and weight - McCune's model (control arm)&#xD;
&#xD;
        2. a method that also considers a pharmacogenetic factor (variants occurring in the&#xD;
           promoter region of the GSTA1 gene) in association with the co-administered&#xD;
           chemotherapeutic agent fludarabine in the dose personalization (experimental arm)&#xD;
&#xD;
      This is an international study being carried out in five countries (Canada, Italy,&#xD;
      Switzerland, France, and Denmark).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 15, 2021</start_date>
  <completion_date type="Anticipated">June 2025</completion_date>
  <primary_completion_date type="Anticipated">June 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Accuracy of the first-dose Bu area under the curve (AUC) prediction</measure>
    <time_frame>1 month</time_frame>
    <description>Proportion of the first doses which result in AUCs within the therapeutic target range defined by the prescriber</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Accuracy of the Bu Clearance prediction</measure>
    <time_frame>1 month</time_frame>
    <description>Absolute prediction error between the predicted and measured Bu clearance of the first dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose adjustment requirement</measure>
    <time_frame>1 month</time_frame>
    <description>Change in percentage between the first dose administered and the next time-wise adjustable dose: 2nd (Bu q24h), 3rd (Bu q12h), or 5th (Bu q6h) doses</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to deliver the personalized dose</measure>
    <time_frame>1 week</time_frame>
    <description>Proportion of personalized doses delivered within the optimal delivery time (to be determined during the first year of the trial)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-related toxicities (TRTs)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of sinusoidal obstruction syndrome (SOS)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of primary and secondary graft failure</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of acute graft-versus-host disease (aGVHD)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>12 months</time_frame>
    <description>Considering as event aGVHD, SOS, relapse and death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Hematopoietic Stem Cell Transplantation</condition>
  <condition>Allogeneic Hematopoietic Stem Cell Transplantation</condition>
  <condition>Autologous Hematopoietic Stem Cell Transplantation</condition>
  <arm_group>
    <arm_group_label>Pharmacogenetic based-model (GSTA1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>The most performing method based on age and weight - McCune's model</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>GSTA1 genotyping</intervention_name>
    <description>Diplotype determination based on 4 single-nucleotide polymorphisms (SNPs) occurring in the promoter region of the GSTA1 gene</description>
    <arm_group_label>Pharmacogenetic based-model (GSTA1)</arm_group_label>
    <arm_group_label>The most performing method based on age and weight - McCune's model</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must be aged from 0-18 years old on entry to the study;&#xD;
&#xD;
          -  Clinical indication of allogeneic or autologous hematopoietic stem cell&#xD;
             transplantation;&#xD;
&#xD;
          -  The conditioning protocol must include IV Bu formulations, Busulfex® (Otsuka&#xD;
             Pharmaceutical), Busilvex® (Pierre Fabre Pharma) or other European Medicines Agency&#xD;
             (EMA) or Food and Drugs Administration (FDA) approved generic formulations regardless&#xD;
             of the administration schedule (q6h, q12h, or q24h)&#xD;
&#xD;
          -  The expected length of time from recruitment to starting the conditioning regimen must&#xD;
             be superior to 10 days;&#xD;
&#xD;
          -  Informed written consent to participate in the study signed by the participant/parent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        • At least one of the drugs listed below scheduled to be administered in the Bu&#xD;
        administration days up to 24h after the last dose of Bu, whenever a washout is not&#xD;
        possible:&#xD;
&#xD;
          -  Metronidazol (required washout: 7 days)&#xD;
&#xD;
          -  Nalidixic acid (required washout: 7 days)&#xD;
&#xD;
          -  Phenytoin (required washout: 21 days)&#xD;
&#xD;
          -  Itraconazole (required washout: 14 days)&#xD;
&#xD;
          -  Ketoconazole (required washout: 7 days)&#xD;
&#xD;
          -  Voriconazole (required washout: 7 days)&#xD;
&#xD;
          -  Deferasirox (required washout: 7 days)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marc Ansari, MD Prof</last_name>
    <phone>+41795536100</phone>
    <email>research@cansearch.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Genève</name>
      <address>
        <city>Geneva</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NAVA Tiago</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>McCune JS, Bemer MJ, Barrett JS, Scott Baker K, Gamis AS, Holford NH. Busulfan in infant to adult hematopoietic cell transplant recipients: a population pharmacokinetic model for initial and Bayesian dose personalization. Clin Cancer Res. 2014 Feb 1;20(3):754-63. doi: 10.1158/1078-0432.CCR-13-1960. Epub 2013 Nov 11.</citation>
    <PMID>24218510</PMID>
  </reference>
  <reference>
    <citation>Nava T, Kassir N, Rezgui MA, Uppugunduri CRS, Huezo-Diaz Curtis P, Duval M, Théoret Y, Daudt LE, Litalien C, Ansari M, Krajinovic M, Bittencourt H. Incorporation of GSTA1 genetic variations into a population pharmacokinetic model for IV busulfan in paediatric hematopoietic stem cell transplantation. Br J Clin Pharmacol. 2018 Jul;84(7):1494-1504. doi: 10.1111/bcp.13566. Epub 2018 Apr 27.</citation>
    <PMID>29469189</PMID>
  </reference>
  <reference>
    <citation>Hassine KB, Nava T et al. 2021 (manuscript submitted).</citation>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 12, 2021</study_first_submitted>
  <study_first_submitted_qc>March 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2021</study_first_posted>
  <last_update_submitted>July 30, 2021</last_update_submitted>
  <last_update_submitted_qc>July 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Geneva</investigator_affiliation>
    <investigator_full_name>Marc Ansari</investigator_full_name>
    <investigator_title>Professeur Marc Ansari</investigator_title>
  </responsible_party>
  <keyword>Precision dosing</keyword>
  <keyword>Pharmacogenetics</keyword>
  <keyword>Children</keyword>
  <keyword>Adolescent</keyword>
  <keyword>Busulfan</keyword>
  <keyword>HSCT</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

